Neoleukin Therapeutics, Inc. (NLTX) |
| 3.49 0.05 (1.45%) 12-18 16:00 |
| Open: | 3.45 |
| High: | 3.59 |
| Low: | 3.42 |
| Volume: | 109,095 |
| Market Cap: | 8(M) |
| PE Ratio: | -0.28 |
| Exchange: | NASDAQ Global Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 18.8 |
| 52w Low: | 3.42 |
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Thu, 14 Dec 2023
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split - Yahoo Finance
Tue, 23 May 2023
Biomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) - Yahoo Finance
Thu, 06 Apr 2023
Neoleukin Therapeutics promotes general counsel to interim CEO - The Business Journals
Wed, 07 Dec 2022
Stephen B Shrewsbury Net Worth (2026) - GuruFocus
Sat, 03 Dec 2022
Abigail Jenkins Net Worth (2026) - GuruFocus
Thu, 11 Aug 2022
Top movers in Thursday's after hours session - ChartMill
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
